Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

NCT01107522 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas

Interventions

DRUG: CTO
DRUG: CTO and Temodar®
DRUG: CTO, Temodar®, Radiation therapy

Sponsor

Tactical Therapeutics, Inc.